Is Satclizumab (Acepin) produced by Roche?

Satralizumab (Satralizumab) is a drug developed by Chugai The recombinant humanized monoclonal antibody against the human interleukin-6 (IL-6) receptor developed by Pharmaceutical and Roche is uniquely formulated using "recycled antibody technology", in which the binding of satelizumab to the IL-6 receptor occurs in a pH-dependent manner, which allows satelizumab to bind to the IL-6 receptor until it reaches the endosome, after which the drug may be separated from the receptor and moved back into the plasma to play its role again. Satelizumab is used to treat neuromyelitis optica spectrum disorder (NMOSD), a rare autoimmune inflammatory disease of the central nervous system (CNS) involving demyelinating lesions of the optic nerve, spinal cord, brainstem, and brain.